National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
Quick Links
Director's Corner
Updates from the Director

Dictionary of Cancer Terms
Cancer-related terms

NCI Drug Dictionary
Definitions, names, and links

Funding Opportunities
Research and training

NCI Publications
Order/download free booklets

Advisory Boards and Groups
Information, meetings, reports

Science Serving People
Learn more about NCI

Español
Información en español
Quit Smoking Today
NCI Highlights
Report to Nation Finds Declines in Cancer Incidence, Death Rates

High Dose Chemotherapy Prolongs Survival for Leukemia

Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E

The Nation's Investment in Cancer Research FY 2009

Past Highlights
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

anti-CD200 monoclonal antibody ALXN6000
A humanized monoclonal antibody directed against the human immunosuppressive molecule CD200 (OX-2) with potential immunomodulating and antineoplastic activities. Anti-CD200 monoclonal antibody ALXN6000 binds to CD200, blocking the binding of CD200 to its receptor, CD200R, present on cells of the macrophage lineage; inhibition of CD200 may augment the cytotoxic T-lymphocyte (CTL) mediated immune response against CD200-expressing tumor cells. CD200 is a type 1a transmembrane protein, related to the B7 family of co-stimulatory receptors, and is upregulated on the surface of multiple hematologic malignant cells; this transmembrane protein appears to be involved in the downregulation of a Th1 (helper T cell) immune response. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Code name:ALXN6000



Previous:anti-CD137 monoclonal antibody, anti-CD19 fully human monoclonal antibody MDX-1342, anti-CD19-DM4 immunoconjugate SAR3419, anti-CD20 monoclonal antibody AME-133v, anti-CD20 monoclonal antibody R7159
Next:anti-CD22 immunotoxin CAT-8015, anti-CD3 immunotoxin A-dmDT390-bisFv(UCHT1), anti-CD30 monoclonal antibody MDX-1401, anti-CD30 monoclonal antibody XmAb2513, anti-CD33 monoclonal antibody-DM4 conjugate AVE9633

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov